首页ALNOV • EPA
Novacyt SA
€0.72
9月30日, GMT+2 13:12:52 · EUR · EPA · 免责声明
股票在FR上市的证券
昨日收盘价
€0.75
当日价格范围
€0.72 - €0.76
年度波幅
€0.45 - €1.59
市值
5218.46万 EUR
平均交易量
208.88万
市盈率
-
股息率
-
主要交易所
EPA
市场资讯
财务信息
损益表
收入
净收入
(GBP)2023年12月年同比变化
收入
412.00万81.82%
经营支出
1251.70万48.31%
净收入
-997.20万-17.10%
净利润率
-242.0435.59%
每股收益
息税折旧摊销前利润
-710.15万-41.10%
有效税率
2.93%
总资产
负债总额
(GBP)2023年12月年同比变化
现金及短期投资
4406.30万-49.34%
总资产
1.34亿-5.03%
负债总额
4657.30万81.32%
权益总额
8724.20万
发行在外的股份
7062.62万
市净率
0.60
资产回报率
-21.46%
资本回报率
-28.44%
现金净变动
(GBP)2023年12月年同比变化
净收入
-997.20万-17.10%
来自运营的现金
-965.00万-59.94%
投资现金
-747.25万-3,853.70%
融资现金
-171.65万-1,360.85%
现金净变动
-1884.00万-197.44%
自由现金流
-380.72万-56.02%
简介
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
成立时间
2006
员工数量
237
搜索
清除搜索内容
关闭搜索框
Google 应用
主菜单